Considering the molecular subtypes of primary breast cancer were not the same (shown as Table 1), the correlation between the efficacy of sintilimab and molecular features including HER2 expression, hormone receptor (HR) status, and the Ki67 level was all analyzed in this study. This evidence concerns the gene NR4A1 and breast carcinoma.